TherapeuticsMD, Inc. is an American pharmaceutical company committed to advancing the health of women throughout their lifecycle.

According to the law firm press release, the Complaint alleges that throughout the class period, TherapeuticsMD engaged in a scheme to deceive the market and cause the Company's stock to trade at artificially inflated prices. In particular, the Complaint alleges that TherapeuticsMD made false and/or misleading statements and/or failed to disclose that: (i) the Company's New Drug Application (NDA) submission for TX-004HR was deficient; (ii) the NDA submission for TX-004HR was not supported by the complete TX-004HR clinical program and/or the clinical program was deficient; (iii) the deficient NDA would likely cause a delay of the FDA's potential approval of the TX-004HR NDA.

On April 10, 2017, TherapeuticsMD issued a press release announcing that the U.S. Food and Drug Administration had identified deficiencies in its NDA for TX-004HR. Following this news, shares of TherapeuticsMD fell more than 19% to close at $6.20 per share on April 10, 2017.

Pursuant to a Notice of Voluntary Dismissal, this case was ordered dismissed on July 21, 2017.